Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $198 from $166 and keeps a Neutral rating on the shares following the Q3 report. Citi views the shares as fairly valued but believes Krystal is well positioned into its 2026 pipeline readouts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech Reports Strong Q3 2025 Performance
- Krystal Biotech’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Krystal Biotech price target raised to $220 from $216 at Chardan
- Positive Outlook for Krystal Biotech: Growth Potential Driven by Vyjuvek, Clinical Pipeline, and Global Expansion
- Krystal Biotech price target raised to $217 from $212 at Clear Street